Transgenic mouse models supporting innate immune function
By inactivating the mouse Flt3 allele and expressing human FLT3L in NSG mice, the challenge of impaired human stem cell engraftment and immune cell development is addressed, resulting in enhanced support for a diverse range of human innate immune cells.
Patent Information
- Application Number
- JP2024165250
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2019-02-13
- Filing Date
- 2024-09-24
- Publication Date
- 2024-12-05
AI Technical Summary
Existing mouse models, such as NSG mice, exhibit impaired development of human hematopoietic stem cells into dendritic cell populations due to human FLT3L activating host mouse FLT3 receptors, leading to reduced human stem cell engraftment and impaired innate immune system support.
Development of NSG mice with an inactivated mouse Flt3 allele and expression of human FLT3L, which prevents human FLT3L from binding to mouse FLT3 receptors, allowing for enhanced human hematopoietic stem cell engraftment and development of various human innate immune cells.
The modified NSG mice support the development of human hematopoietic stem cells into diverse immune cell types, including dendritic cells, natural killer cells, and monocyte-macrophages, with increased percentages of these cells compared to control mice, facilitating a robust human innate immune system.
Smart Images

Figure 2024169631000002 
Figure 2024169631000003 
Figure 2024169631000004
Abstract
Description
[Technical field]
[0001] Government Permit Rights This invention was made with Government support under Grant No. 1R01132963 awarded by the National Institutes of Health. The Government has certain rights in this invention.
[0002] Related Applications This application claims the benefit under 35 U.S.C. §119(e) of U.S. Provisional Patent Application No. 62 / 805,257, filed February 13, 2019, which is incorporated by reference in its entirety. [Background technology]
[0003] background Signaling through the fms-related tyrosine kinase 3 (FLT3) receptor supports the survival, proliferation, and differentiation of hematopoietic progenitor cells and dendritic cells (DCs) (1, 2). Human DCs are necessary to present antigens to human T cells and are required for the development of robust human immune responses (4). Mature human DCs also produce interleukin-15 and other factors that support the development of natural killer (NK) cells and other components of the human innate immune system (5). [Prior art documents] [Non-patent literature]
[0004] [Non-Patent Document 1] P. Tsapogas, CJ Mooney, G. Brown, A. Rolink, The Cytokine Flt3-Ligand in Normal and Malignant Hematopoiesis. International journal of molecular sciences 18, (2017). [Non-Patent Document 2] CJ Mooney, A. Cunningham, P. Tsapogas, KM Toellner, G. Brown, Selective Expression of Flt3 within the Mouse Hematopoietic Stem Cell Compartment. International journal of molecular sciences 18, (2017). [Non-Patent Document 3] K. Palucka, J. Banchereau, Cancer immunotherapy via dendritic cells. Nature reviews. Cancer 12, 265-277 (2012). [Non-Patent Document 4] JS Do, B. Min, IL-15 produced and trans-presented by DCs underlies homeostatic competition between CD8 and {gamma}{delta} T cells in vivo. Blood 113, 6361-6371 (2009). Summary of the Invention [Means for solving the problem]
[0005] Abstract In some embodiments, the immunodeficient NOD.Cg-Prkdc vector comprises a nucleic acid encoding human FLT3L (e.g., a human FLT3L transgene) and an inactivated mouse Flt3 allele. scid Il2rg tm1Wjl / SzJ(NSG TM ) mice ("NOD scid gamma" mice) are provided herein. TM Mice support human hematopoietic stem cell (HSC) engraftment, but they show impaired development of human HSC into dendritic cell (DC) populations (3). To provide a mouse model that supports development of human HSC into DC populations, we developed a transgenic NSG mouse model expressing human FLT3L.TM Mouse (NSG TM Unexpectedly, however, human HSC engraftment was not observed in NSG TM Compared to the control, NSG TM -Tg(Hu-FLT3L) mice. TM To understand the phenotype observed in NSG-Tg(Hu-FLT3L) mice, the endogenous mouse receptor for FLT3L, Flt3, was knocked out. Surprisingly, this transgenic line (herein NSG TM Flt3 null The engraftment of human HSCs from human FLT3L-Tg (Hu-FLT3L) mice was confirmed by the following: (1) human CD3 + T cells and human CD33 + (2) significantly increased percentages of myeloid cells and (3) human CD123 + Plasmacytoid dendritic cells, CD56 + Human natural killer (NK) cells, CD14 + Human monocytes / macrophages, and CD11C + HLA-DR + (3) increased percentage of human myeloid dendritic cells and human CD45 + Support for mucosal adhesion of cells. TM The decreased human HSC engraftment in -Tg(Hu-FLT3L) may have been the result of human FLT3L activation via the host mouse FLT3 receptor, host mouse DCs and possibly other mouse components of innate immunity.
[0006] Accordingly, some aspects of the disclosure relate to nucleic acids encoding human FLT3L and NSGs comprising an inactivated mouse Flt3 allele. TM Mouse (NSG TM Flt3 null We provide a mouse model that supports the development of HSCs into many different cell types of the human innate immune system, including dendritic cells.
[0007] In some embodiments, the mouse comprises a genomic modification that inactivates a mouse Flt3 allele. In some embodiments, the genomic modification is in at least one region of the mouse Flt3 allele selected from a coding region, a non-coding region, and a regulatory region. In some embodiments, the genomic modification is in at least one coding region of the mouse Flt3 allele. For example, the genomic modification can be in exon 6, exon 7, and / or exon 8. In some embodiments, the genomic modification is selected from a genomic deletion, a genomic insertion, a genomic replacement, and combinations thereof. For example, the genomic modification can be a genomic deletion. The mouse Flt3 allele can comprise, for example, a genomic deletion of a nucleotide sequence in exon 6, exon 7, and exon 8.
[0008] In some embodiments, the nucleic acid sequence of SEQ ID NO:5 is deleted from the mouse Flt3 allele.
[0009] In some embodiments, the modified mouse Flt3 allele comprises the nucleic acid sequence of SEQ ID NO:6.
[0010] In some embodiments, the nucleic acid encoding the human FLT3L comprises a human FLT3L transgene. In some embodiments, the human FLT3L transgene comprises the nucleic acid sequence of SEQ ID NO: 7. In some embodiments, the mouse expresses human FLT3L. The human FLT3L may be expressed, for example, at a level of at least 10,000 pg / ml. In some embodiments, the human FLT3L is expressed at a level of 10,000 pg / ml to 30,000 pg / ml. For example, the human FLT3L may be expressed at a level of 15,000±1000 pg / mL to 17,000±100 pg / ml.
[0011] In some embodiments, the mouse expresses mouse FLT3L. In some embodiments, the mouse FLT3L is expressed at a level of at least 2,000 pg / ml. For example, the mouse FLT3L may be expressed at a level of 5,000 pg / ml to 10,000 pg / ml. In some embodiments, the mouse FLT3L is expressed at a level of 6,000 pg / ml to 8,000 pg / ml.
[0012] In some embodiments, the mouse does not express detectable levels of mouse FLT3. In some embodiments, the detectable level of mouse FLT3 expressed by the mouse is less than 1,000 pg / ml.
[0013] In some embodiments, the mouse expresses a detectable number of CD135 + Lacking multipotent progenitor cells.
[0014] In some embodiments, the mouse expresses human CD34 + The human CD34 + Hematopoietic stem cells, in some embodiments, are derived from human umbilical cord blood, bone marrow, or mobilized peripheral blood.
[0015] In some embodiments, the mouse expresses human CD45 + The population of human CD45 cells + In some embodiments, the population of cells comprises human CD45 + / CD3 + T cells and / or human CD45 + / CD33 + Contains myeloid cells.
[0016] In some embodiments, the human CD45 + The population of cells was NOD scid Increased percentage of human CD45 expression relative to gamma control mice or NOD scid gamma-Hu-FLT3L control mice + / CD3 + For example, human CD45 T cells in the above mice + / CD3 + The percentage of T cells may be increased by at least 25%, at least 50%, or at least 100%.
[0017] In some embodiments, the human CD45 + The population of cells was NOD scid Increased percentage of human CD45 expression relative to gamma control mice or NOD scid gamma-Hu-FLT3L control mice + / CD33 + For example, human CD45 + / CD33 + The percentage of myeloid cells may be increased by at least 25%, at least 50%, or at least 100%.
[0018] In some embodiments, the mice have an increased percentage of human CD123 relative to NOD scid gamma control mice or NOD scid gamma-Hu-FLT3L control mice. + For example, human CD123 in the above mouse + The percentage of plasmacytoid dendritic cells may be increased by at least 25%, at least 50%, or at least 100%.
[0019] In some embodiments, the mice have an increased percentage of human CD56 relative to NOD scid gamma control mice or NOD scid gamma-Hu-FLT3L control mice. + Natural killer cells. For example, human CD56 + The percentage of natural killer cells may be increased by at least 25%, at least 50%, or at least 100%.
[0020] In some embodiments, the mice have an increased percentage of human CD14 relative to NOD scid gamma control mice or NOD scid gamma-Hu-FLT3L control mice. + Monocytes and macrophages. For example, human CD14 + The percentage of monocytes-macrophages may be increased by at least 25%, at least 50%, or at least 100%.
[0021] In some embodiments, the mice have an increased percentage of human CD11C relative to NOD scid gamma control mice or NOD scid gamma-Hu-FLT3L control mice. + HLA-DR + Myeloid dendritic cells. For example, human CD11C + HLA-DR + The percentage of myeloid dendritic cells is increased by at least 25%, at least 50%, or at least 100%.
[0022] In some embodiments, the mouse expresses human CD45 in the small intestine of the mouse. + Mucosal engraftment of cells is shown.
[0023] Another aspect of the present disclosure is a method for the treatment of a mouse according to any one of claims 1 to 23, comprising the steps of: sublethally irradiating the mouse with human CD34 + A method is provided that includes injecting hematopoietic stem cells.
[0024] In some embodiments, the method further comprises administering to the mouse an agent of interest. In some embodiments, the method comprises evaluating the effect of the agent on human immune cells in the mouse.
[0025] In some embodiments, the method further comprises that the human immune cells are selected from T cells, dendritic cells, natural killer cells, and macrophages.
[0026] Yet another aspect of the present disclosure is the use of NOD.Cg-Prkdc scid Il2rg tm1Wjl The present invention provides a method for the treatment of rhabdomyolysis, comprising the steps of: injecting a nucleic acid encoding human FLT3L into the pronucleus of a . / SzJ (NOD scid gamma) mouse; generating an NSG Tg(Hu-FLT3L) mouse; and inactivating the mouse Flt3 allele in the NSG Tg(Hu-FLT3L) mouse.
[0027] Yet another aspect of the present disclosure is the use of NOD.Cg-Prkdc scid Il2rg tm1Wjl Inactivation of the mouse Flt3 allele in / SzJ (NOD scid gamma) mice results in the expression of NSG Flt3 null generating a mouse, and null A method is provided that includes injecting a nucleic acid encoding human FLT3L into the pronucleus of a mouse.
[0028] Yet another aspect of the present disclosure is a method for the preparation of a Prkdc scid Homozygous for Il2rg tm1Wjl Homozygous for Flt3 null Female mice homozygous for the Prkdc transgene and homozygous for the human FLT3L transgene were scid Homozygous for X-linked Il2rg tm1Wjl Hemizygous for Flt3 null and a male mouse homozygous for the human FLT3L transgene to generate offspring mice.
[0029] Furthermore, some aspects of the disclosure include a NOD.Cg-Prkdc vector comprising a nucleic acid encoding human FLT3L and an inactivated endogenous Flt3 allele. scid Il2rg tm1Wjl / SzJ cells are provided.
[0030] Yet another aspect of the present disclosure provides a transgenic rodent comprising a nucleic acid encoding human FLT3L and a cell comprising an inactivated endogenous Flt3 allele. In some embodiments, the transgenic rodent is a transgenic mouse.
[0031] Some aspects of the present disclosure provide a gRNA targeting mouse Flt3, optionally wherein the gRNA targets exon 6 or exon 8 of mouse Flt3. In some embodiments, the gRNA comprises the sequence of SEQ ID NO: 1. In some embodiments, the gRNA comprises the sequence of SEQ ID NO: 2.
[0032] Also provided herein is a mouse oocyte comprising any one of the gRNAs described herein. In some embodiments, the mouse oocyte is fertilized.
[0033] Some aspects further provide a mouse oocyte comprising a first gRNA targeting exon 6 of mouse Flt3 and a second gRNA targeting exon 8 of mouse Flt3, optionally wherein the mouse oocyte is fertilized.
[0034] The mouse oocyte, in some embodiments, further comprises Cas9 mRNA and / or Cas9 protein.
[0035] The mouse oocyte, in some embodiments, further comprises a human FLT3L transgene. [Brief description of the drawings]
[0036] [Figure 1]Figure 1 shows human FLT3L levels in serum of NSGTM-transgenic mice expressing human FLT3L that are hemizygous (denoted as Het) or homozygous (denoted as hom) for human FLT3L derived from founder lines 7 and 8 (NSGTM-Tg(Hu-FLT3L). Each bar represents values from 3-4 female or male mice aged 5-15 weeks. [Diagram 2] Figure 2 shows reduced levels of human hematopoietic stem cell (HSC) engraftment in homozygous NSGTM-Tg(Hu-FLT3L) mice expressed as a percentage of human CD45+ cells in the blood. Each data point represents the percentage of human CD45+ cells in an individual mouse tested 6-15 weeks post-engraftment. Both male and female mice were tested. [Diagram 3] Figure 3 shows the absence of mouse CD135+ myeloid multipotent (MMP3) progenitor cells in NSGTM Flt3null-Tg (Hu-FLT3L) mouse bone marrow. Each bar represents values from three 10-week-old female mice. [Figure 4] Figure 4A shows mouse FLT3L levels in NSGTMFl3null-Tg (Hu-FLT3L) and NSGTM control mice. Figure 4B shows human FLT3L levels in NSGTM Flt3null-Tg (Hu-FLT3L) and NSGTM control mice. [Diagram 5]Figure 5A shows human CD45+ T cell development in NSGTM Flt3null-Tg(Hu-FLT3L) mice engrafted with human HSCs and CD45+ T cell development in NSGTM control mice. Eight NSGTM Flt3null-Tg(Hu-FLT3L) mice and ten NSGTM control mice were injected at 8-12 weeks of age. Both male and female mice were used. Figure 5B shows increased percentage human CD3+ T cell development in NSGTM Flt3null-Tg(Hu-FLT3L) mice engrafted with human HSCs compared to NSGTM control mice. Figure 5C shows decreased percentage human CD20+ B cell development in NSGTM Flt3null-Tg(Hu-FLT3L) mice engrafted with human HSCs compared to NSGTM control mice. This may be due to an increased percentage of HSCs differentiating into innate immune system cells (e.g., dendritic cells, natural killer cells, monocytes, macrophages, eosinophils, basophils, neutrophils) as opposed to adaptive immune system cells (e.g., T cells and B cells). Figure 5D shows an increased percentage of human CD33+ myeloid cell development in NSGTM Flt3null-Tg (Hu-FLT3L) mice engrafted with human HSCs compared to NSGTM control mice. [Figure 6]Figure 6A shows increased human CD123+ plasmacytoid dendritic cell (DC) development in NSGTM Flt3null-Tg(Hu-FLT3L) mice engrafted with human HSCs compared to NSGTM control mice. Eight NSGTM Flt3null-Tg(Hu-FLT3L) mice and ten NSGTM control mice were injected at 8-12 weeks of age. Both male and female mice were used. Figure 6B shows increased human CD56+ natural killer cell (NK) development in NSGTM Flt3null-Tg(Hu-FLT3L) mice engrafted with human HSCs compared to NSGTM control mice. Figure 6C shows increased human CD14+ monocyte / macrophage cell development in NSGTM Flt3null-Tg(Hu-FLT3L) mice engrafted with human HSCs compared to NSGTM control mice. FIG. 6D shows increased human CD11c / HLA-DR+ myeloid DC cell development in NSGTM Flt3null-Tg (Hu-FLT3L) mice engrafted with human HSCs compared to NSGTM control mice. [Figure 7] Figure 7 shows the small intestine of NSGTM Flt3null-Tg(Hu-FLT3L) and NSGTM control mice showing mucosal engraftment associated with HSCs. Eight NSGTM Flt3null-Tg(Hu-FLT3L) mice and ten NSGTM control mice were injected at 8-12 weeks of age. Both male and female mice were used. [Figure 8A]FIG. 8A shows comparable human CD45+ cell development in NSGTM Flt3null-Tg(Hu-FLT3L) mice engrafted with human HSCs compared to NSGTM control mice. FIG. 8B shows increased human CD33+ myeloid cell development in NSGTM Flt3null-Tg(Hu-FLT3L) mice engrafted with human HSCs compared to NSGTM control mice. FIG. 8C shows increased human CD3+ T cell development in NSGTM Flt3null-Tg(Hu-FLT3L) mice engrafted with human HSCs compared to NSGTM control mice. FIG. 8D shows increased human CD14+ monocytic cell development in NSGTM Flt3null-Tg(Hu-FLT3L) mice engrafted with human HSCs compared to NSGTM control mice. Figure 8E shows increased human CD11c+ HLA-DR+ myeloid dendritic cell development in NSGTM Flt3null-Tg(Hu-FLT3L) mice engrafted with human HSCs compared to NSGTM control mice, and Figure 8F shows increased human CD56+ natural killer (NK) cell development in NSGTM Flt3null-Tg(Hu-FLT3L) mice engrafted with human HSCs compared to NSGTM control mice. [Figure 8B]FIG. 8A shows comparable human CD45+ cell development in NSGTM Flt3null-Tg(Hu-FLT3L) mice engrafted with human HSCs compared to NSGTM control mice. FIG. 8B shows increased human CD33+ myeloid cell development in NSGTM Flt3null-Tg(Hu-FLT3L) mice engrafted with human HSCs compared to NSGTM control mice. FIG. 8C shows increased human CD3+ T cell development in NSGTM Flt3null-Tg(Hu-FLT3L) mice engrafted with human HSCs compared to NSGTM control mice. FIG. 8D shows increased human CD14+ monocytic cell development in NSGTM Flt3null-Tg(Hu-FLT3L) mice engrafted with human HSCs compared to NSGTM control mice. Figure 8E shows increased human CD11c+ HLA-DR+ myeloid dendritic cell development in NSGTM Flt3null-Tg(Hu-FLT3L) mice engrafted with human HSCs compared to NSGTM control mice, and Figure 8F shows increased human CD56+ natural killer (NK) cell development in NSGTM Flt3null-Tg(Hu-FLT3L) mice engrafted with human HSCs compared to NSGTM control mice. [Figure 8C]FIG. 8A shows comparable human CD45+ cell development in NSGTM Flt3null-Tg(Hu-FLT3L) mice engrafted with human HSCs compared to NSGTM control mice. FIG. 8B shows increased human CD33+ myeloid cell development in NSGTM Flt3null-Tg(Hu-FLT3L) mice engrafted with human HSCs compared to NSGTM control mice. FIG. 8C shows increased human CD3+ T cell development in NSGTM Flt3null-Tg(Hu-FLT3L) mice engrafted with human HSCs compared to NSGTM control mice. FIG. 8D shows increased human CD14+ monocytic cell development in NSGTM Flt3null-Tg(Hu-FLT3L) mice engrafted with human HSCs compared to NSGTM control mice. Figure 8E shows increased human CD11c+ HLA-DR+ myeloid dendritic cell development in NSGTM Flt3null-Tg(Hu-FLT3L) mice engrafted with human HSCs compared to NSGTM control mice, and Figure 8F shows increased human CD56+ natural killer (NK) cell development in NSGTM Flt3null-Tg(Hu-FLT3L) mice engrafted with human HSCs compared to NSGTM control mice. [Figure 8D]FIG. 8A shows comparable human CD45+ cell development in NSGTM Flt3null-Tg(Hu-FLT3L) mice engrafted with human HSCs compared to NSGTM control mice. FIG. 8B shows increased human CD33+ myeloid cell development in NSGTM Flt3null-Tg(Hu-FLT3L) mice engrafted with human HSCs compared to NSGTM control mice. FIG. 8C shows increased human CD3+ T cell development in NSGTM Flt3null-Tg(Hu-FLT3L) mice engrafted with human HSCs compared to NSGTM control mice. FIG. 8D shows increased human CD14+ monocytic cell development in NSGTM Flt3null-Tg(Hu-FLT3L) mice engrafted with human HSCs compared to NSGTM control mice. Figure 8E shows increased human CD11c+ HLA-DR+ myeloid dendritic cell development in NSGTM Flt3null-Tg(Hu-FLT3L) mice engrafted with human HSCs compared to NSGTM control mice, and Figure 8F shows increased human CD56+ natural killer (NK) cell development in NSGTM Flt3null-Tg(Hu-FLT3L) mice engrafted with human HSCs compared to NSGTM control mice. [Figure 8E]FIG. 8A shows comparable human CD45+ cell development in NSGTM Flt3null-Tg(Hu-FLT3L) mice engrafted with human HSCs compared to NSGTM control mice. FIG. 8B shows increased human CD33+ myeloid cell development in NSGTM Flt3null-Tg(Hu-FLT3L) mice engrafted with human HSCs compared to NSGTM control mice. FIG. 8C shows increased human CD3+ T cell development in NSGTM Flt3null-Tg(Hu-FLT3L) mice engrafted with human HSCs compared to NSGTM control mice. FIG. 8D shows increased human CD14+ monocytic cell development in NSGTM Flt3null-Tg(Hu-FLT3L) mice engrafted with human HSCs compared to NSGTM control mice. Figure 8E shows increased human CD11c+ HLA-DR+ myeloid dendritic cell development in NSGTM Flt3null-Tg(Hu-FLT3L) mice engrafted with human HSCs compared to NSGTM control mice, and Figure 8F shows increased human CD56+ natural killer (NK) cell development in NSGTM Flt3null-Tg(Hu-FLT3L) mice engrafted with human HSCs compared to NSGTM control mice. [Figure 8F]FIG. 8A shows comparable human CD45+ cell development in NSGTM Flt3null-Tg(Hu-FLT3L) mice engrafted with human HSCs compared to NSGTM control mice. FIG. 8B shows increased human CD33+ myeloid cell development in NSGTM Flt3null-Tg(Hu-FLT3L) mice engrafted with human HSCs compared to NSGTM control mice. FIG. 8C shows increased human CD3+ T cell development in NSGTM Flt3null-Tg(Hu-FLT3L) mice engrafted with human HSCs compared to NSGTM control mice. FIG. 8D shows increased human CD14+ monocytic cell development in NSGTM Flt3null-Tg(Hu-FLT3L) mice engrafted with human HSCs compared to NSGTM control mice. Figure 8E shows increased human CD11c+ HLA-DR+ myeloid dendritic cell development in NSGTM Flt3null-Tg(Hu-FLT3L) mice engrafted with human HSCs compared to NSGTM control mice, and Figure 8F shows increased human CD56+ natural killer (NK) cell development in NSGTM Flt3null-Tg(Hu-FLT3L) mice engrafted with human HSCs compared to NSGTM control mice. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0037] Detailed Description NSG TM Flt3 null -Tg(Hu-FLT3L) mice The present disclosure provides a nucleic acid encoding human FLT3L and a NOD.Cg-Prkdc vector comprising an inactivated mouse Flt3 allele. scid Il2rg tm1Wjl / SzJ (NSG TM ) mice, which are herein TM Flt3 null These mice are called -Tg(Hu-FLT3L) mice.
[0038] The above NSG TMThese mice are immunodeficient mice that lack mature T cells, B cells, and natural killer (NK) cells, are defective in multiple cytokine signaling pathways, and have numerous defects in innate immunity (see, e.g., Shultz LD et al. Nat. Rev. Immunol. 2007; 7 (2): 118-130; Shultz LD et al. 2005; J. Immunol. 174 (10): 6477-89; and Shultz LD et al. J. Immunol. 1995; 154 (1): 180-91). TM Mice (derived from the non-obese diabetic (NOD) mouse strain NOD / ShiLtJ (see, e.g., Makino S et al. Jikken Dobutsu 1980; 29 (1): 1-13)) were transfected with Prkdc scid mutation (also called "severe combined immunodeficiency" or "scid" mutation) and Il2rg tm1Wjl Targeted mutations are included. scid The mutation is a loss-of-function mutation in the mouse homologue of the human PRKDC gene - this mutation essentially eliminates adaptive immunity (e.g., Greiner DL et al. 1998; Stem Cells 16 (3): 166-177; and Blunt T et al. 1995; (See Cell 80 (5): 813-23). The Il2rg tm1Wjl The mutation is a null mutation in the gene encoding the interleukin 2 receptor gamma chain (IL2Rγ, homologous to IL2RG in humans), which blocks NK cell differentiation, thereby removing the obstacle that prevents efficient engraftment of primary human cells (Shultz LD et al. 2005; Greiner et al. 1998; and Cao X. et al. Immunity 1995; 2 (3): 223-38). Loss-of-function mutations, as known in the art, result in a gene product that has little or no function. By comparison, null mutations result in a gene product that has no function. The inactivating allele can be a loss-of-function allele or a null allele.
[0039] NSGs provided hereinTM Flt3 null The -Tg(Hu-FLT3L) mouse comprises a nucleic acid encoding human FLT3L. FLT3L (e.g., NC_000019.10; chromosome:GRCh38:19:49473607:49486831:1) is a cytokine and growth factor that stimulates the generation of immune cells (e.g., B cells and T cells) by binding and activating the FLT3 receptor (see, e.g., Klein O. et al. Eur J Immunol. 2013; 43(2): 533-539). FLT3L is important for steady-state dendritic cell development. In some embodiments, the nucleic acid encoding the human FLT3L comprises a human FLT3L transgene. Surprisingly, data described herein indicate that human FLT3L can bind mouse FLT3, which, without being bound by theory, can activate innate mouse immunity. Thus, in some embodiments, the NSGs provided herein TM The mouse comprises a nucleic acid (eg, DNA) encoding human FLT3L and an inactivated mouse Flt3 allele.
[0040] The nucleic acid may be DNA, RNA, or a chimera of DNA and RNA. In some embodiments, the nucleic acid (e.g., DNA) encoding human FLT3L comprises a gene encoding FLT3L. A gene is a sequence of nucleotides (DNA or RNA) that encodes a functional molecule (e.g., a protein). A gene may be endogenous (naturally occurring in a host organism) or exogenous (transferred into a host organism naturally or via genetic engineering). An allele arises by mutation and is one of two or more alternative forms of a gene found at the same locus on a chromosome. In some embodiments, a gene comprises a promoter sequence, a coding region (e.g., exons), a non-coding region (e.g., introns), and a regulatory region (also referred to as a regulatory sequence). As known in the art, a promoter sequence is a DNA sequence where transcription of a gene begins. A promoter sequence is typically located immediately upstream of the transcription start site (the 5' end of the transcription site). An exon is a region of a gene that codes for amino acids. An intron (and other non-coding DNA) is a region of a gene that does not code for amino acids.
[0041] A mouse comprising a human gene is considered to comprise a human transgene. A transgene is a gene exogenous to a host organism. That is, a transgene is a gene that is transferred to a host organism naturally or through genetic engineering. A transgene does not naturally occur in a host organism (an organism comprising said transgene, e.g., a mouse). In some embodiments, a mouse as provided herein comprises a FLT3L transgene (e.g., a human FLT3L transgene). In some embodiments, said human FLT3L transgene is integrated into the mouse genome. In some embodiments, said human FLT3L transgene comprises the nucleic acid sequence of SEQ ID NO:7.
[0042] An inactivated allele is an allele that does not produce detectable levels of a functional gene product (e.g., a functional protein). In some embodiments, an inactivated allele is not transcribed. In some embodiments, an inactivated allele does not encode a functional protein. Thus, a mouse comprising an inactivated mouse Flt3 allele does not produce detectable levels of functional FLT3. In some embodiments, a mouse comprising an inactivated mouse Flt3 allele does not produce any functional FLT3.
[0043] In some embodiments, mice (e.g., NSG TM Flt3 null -Tg(Hu-FLT3L) mice) contain genomic modifications that inactivate the mouse Flt3 allele. Modification, in terms of nucleic acid, is any manipulation of a nucleic acid relative to its corresponding wild-type nucleic acid (e.g., naturally occurring nucleic acid). Thus, genomic modification is any manipulation of a nucleic acid in a genome relative to its corresponding wild-type nucleic acid (e.g., naturally occurring nucleic acid) in a genome. Non-limiting examples of nucleic acid (e.g., genomic) modifications include deletions, insertions, "indels" (deletions and insertions), and substitutions (e.g., point mutations). In some embodiments, deletions, insertions, indels, or other modifications in a gene result in a frameshift mutation such that the gene no longer encodes a functional product (e.g., a protein). Modifications also include chemical modifications, such as chemical modifications of at least one nucleic acid base. Methods of nucleic acid modification (e.g., those that result in gene inactivation) are known and include, but are not limited to, RNA interference, chemical modification, and gene editing (e.g., using recombinases or other programmable nuclease systems (e.g., CRISPR / Cas, TALEN, and / or ZFN)). In some embodiments, CRISPR / Cas gene editing is used to inactivate mouse Flt3 alleles, as described elsewhere herein.
[0044] In some embodiments, the genomic modification (e.g., a deletion or indel) is in (at least one) region of the mouse Flt3 allele selected from a coding region, a non-coding region, and a regulatory region. In some embodiments, the genomic modification (e.g., a deletion or indel) is in a coding region of the mouse Flt3 allele. For example, the genomic modification (e.g., a deletion or indel) may be in exon 6, exon 7, exon 8 of the mouse Flt3 allele, or may span exons 6-8. In some embodiments, the genomic modification is a genomic deletion. For example, the mouse Flt3 allele may include a genomic deletion of nucleotide sequences in exon 6, exon 7, and exon 8. In some embodiments, the nucleotide sequence of SEQ ID NO:5 is deleted from the inactivated mouse Flt3 allele. In some embodiments, the inactivated mouse Flt3 allele includes the nucleotide sequence of SEQ ID NO:6.
[0045] NSGs provided herein TM Flt3 null-Tg(Hu-FLT3L) mice, in some embodiments, express human FLT3L, hi some embodiments, human FLT3L is expressed at a level of at least 5,000 pg / ml or at least 10,000 pg / ml. For example, human FLT3L can be expressed at a level of at least 5,000pg / ml, 7,500pg / ml, 10,000pg / ml, 12,500pg / ml, 15,000pg / ml, 17,500pg / ml, 20,000pg / ml, 22,500pg / ml, 25,000pg / ml, 27,500pg / ml, 30,000pg / ml, 32,500pg / ml, 35,000pg / ml, 37,500pg / ml, 40,000pg / ml, 42,500pg / ml, 45,000pg / ml, 47,500pg / ml, or 50,000pg / ml. In some embodiments, human FLT3L is expressed at a level of 10,000 pg / ml to 30,000 pg / ml. In some embodiments, human FLT3L is expressed at a level of 15,000±1000 pg / mL to 17,000±100 pg / ml. Methods for detecting FLT3L protein expression are known and can be used as provided herein. For example, flow cytometry and / or ELISA (enzyme-linked immunosorbent assay) using anti-FLT3L antibodies can be used to detect the level of human FLTL3 protein present in mouse tissues and / or blood.
[0046] In some embodiments, the NSG TM Flt3 nullThe --Tg(Hu-FLT3L) mouse may also express mouse FLTL3. In some embodiments, mouse FLT3L is expressed at a level of at least 1,000 pg / ml or at least 2,000 pg / ml. For example, mouse FLT3L may be expressed at a level of 3,000 pg / ml, 4,000 pg / ml, 5,000 pg / ml, 6,000 pg / ml, 7,000 pg / ml, 8,000 pg / ml, 9,000 pg / ml, or 10,000 pg / ml. In some embodiments, mouse FLT3L is expressed at a level of 5,000 pg / ml to 10,000 pg / ml. In some embodiments, mouse FLT3L is expressed at a level of 6,000 pg / ml to 8,000 pg / ml.
[0047] In some embodiments, the NSG TM Flt3 null -Tg(Hu-FLT3L) mice do not express detectable levels of mouse FLT3. A detectable level of mouse FLT3 is any level of FLT3 protein that is detected using a standard protein detection assay (e.g., flow cytometry and / or ELISA). In some embodiments, NSG TM Flt3 null The NSG-Tg(Hu-FLT3L) mice express undetectable or low levels of mouse FLT3. For example, the mice may express less than 1,000 pg / ml of mouse FLT3. TM Flt3 null -Tg(Hu-FLT3L) mice express less than 500 pg / ml of mouse FLT3 or less than 100 pg / ml of mouse FLT3. The mouse FLT3 receptor is also referred to as cluster of differentiation CD135. Thus, in some embodiments, NSG TM Flt3 null -Tg(Hu-FLT3L) mice express CD135 + Containing multipotent progenitor (MPP3) cells (CD135 + (absence of multipotent progenitor (MPP3) cells).
[0048] Human innate immune system model NSG of this disclosure TM Flt3 null In some embodiments, the Tg(Hu-FLT3L) mouse expresses human CD34 + It is used to support the engraftment of HSCs and the development of the human innate immune system. The human immune system includes the innate and adaptive immune systems. The innate immune system is responsible for recruiting immune cells to sites of infection, activating the complement cascade, identifying foreign bodies and removing them from the body by white blood cells, activating the adaptive immune system, and acting as a physical and chemical barrier against infectious agents.
[0049] In some embodiments, the NSG TM Flt3 null Tg(Hu-FLT3L) mice are sublethally irradiated (e.g., 100-300 cGy) to kill endogenous mouse HSCs, and the irradiated mice are then transduced with human CD34 to initiate the development of a human innate immune system. + HSCs (e.g., 50,000-200,000 HSCs). Thus, in some embodiments, the mice are transfected with human CD34 + Further includes HSC. Human CD34 + HSCs may be derived from any source, including, but not limited to, human umbilical cord blood, mobilized peripheral blood, and bone marrow. In some embodiments, the human CD34 + HSCs are derived from human umbilical cord blood.
[0050] Human CD34 +Differentiation of HSCs into various immune cells (e.g., T cells, B cells, dendritic cells) is a complex process in which successive developmental steps are regulated by multiple cytokines. This process can be monitored through cell surface such as cluster of differentiation (CD). For example, CD45 is expressed on the surface of HSCs, macrophages, monocytes, T cells, B cells, natural killer cells, and dendritic cells and can be used as a marker to indicate engraftment. On T cells, CD45 regulates T cell receptor signaling, cell growth, and cell differentiation. In some embodiments, the NSG TM Flt3 null Tg(Hu-FLT3L) mice express human CD45 + Unexpectedly, the above NSG TM Flt3 null Tg(Hu-FLT3L) mice express human CD45 in the small intestine. + In some embodiments, the NSG cells are TM Flt3 null Tg(Hu-FLT3L) mice also express human CD45 in lung, thymus, spleen, and / or lymph node tissues. + Shows cell engraftment.
[0051] CD45 + As cells mature, they begin to express additional biomarkers indicative of various developmental stages and differentiating cell types. For example, differentiating T cells also express CD3, CD4, and CD8. As another example, developing myeloid cells express CD33 + The NSGs of the present disclosure express TM Flt3 null Tg(Hu-FLT3L) mice advantageously express human CD45 + Not only does it contain human CD45 + / CD3 + Double positive T cells and human CD45 + / CD33 + Also includes double positive myeloid cells.
[0052] Thus, in some embodiments, NSGTM Flt3 null Human CD45 in Tg(Hu-FLT3L) mice + The cell population is human CD45 + / CD3 + In some embodiments, the human CD45 T cell is + The population of cells is NSG TM Increased percentage of human CD45 relative to control mice + / CD3 + In some embodiments, the NSG TM Flt3 null Human CD45 in Tg(Hu-FLT3L) mice + / CD3 + The percentage of T cells in NSG TM Increase by at least 25% compared to control mice. For example, TM Flt3 null Human CD45 in Tg(Hu-FLT3L) mice + / CD3 + The percentage of T cells in NSG TM In some embodiments, the NSG expression level may be increased by at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 100% relative to control mice. TM Flt3 null Human CD45 in Tg(Hu-FLT3L) mice + / CD3 + The percentage of T cells in NSG TM In some embodiments, the NSG TM Flt3 null Human CD45 in Tg(Hu-FLT3L) mice + / CD3 + The percentage of T cells in NSG TMIn some embodiments, the NSG TM Flt3 null Human CD45 in Tg(Hu-FLT3L) mice + / CD3 + The percentage of T cells in NSG TM Increase by 25%-100%, 25%-75%, 25%-50%, 50%-100%, 50%-75%, or 75%-100% relative to control mice.
[0053] In some embodiments, the NSG TM Flt3 null Human CD45 in Tg(Hu-FLT3L) mice + The cell population is human CD45 + / CD33 + In some embodiments, the human CD45 T cell is + The population of cells is NSG TM Increased percentage of human CD45 relative to control mice + / CD33 + In some embodiments, the NSG TM Flt3 null Human CD45 in Tg(Hu-FLT3L) mice + / CD33 + The percentage of T cells in NSG TM Increase by at least 25% compared to control mice. For example, TM Flt3 null Human CD45 in Tg(Hu-FLT3L) mice + / CD33 + The percentage of T cells in NSG TM In some embodiments, the NSG expression level may be increased by at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 100% relative to control mice.TM Flt3 null Human CD45 in Tg(Hu-FLT3L) mice + / CD33 + The percentage of T cells in NSG TM In some embodiments, the NSG TM Flt3 null Human CD45 in Tg(Hu-FLT3L) mice + / CD33 + The percentage of T cells in NSG TM In some embodiments, the NSG TM Flt3 null Human CD45 in Tg(Hu-FLT3L) mice + / CD33 + The percentage of T cells in NSG TM Increase by 25%-100%, 25%-75%, 25%-50%, 50%-100%, 50%-75%, or 75%-100% relative to control mice.
[0054] NSGs provided herein TM Flt3 null Tg(Hu-FLT3L) mice can also surprisingly support the engraftment of dendritic cells (e.g., plasmacytoid and myeloid dendritic cells), natural killer cells, and monocyte-derived macrophages (monocyto-macrophages). Plasmacytoid dendritic cells (pDCs) secrete high levels of interferon-α; myeloid dendritic cells (mDCs) secrete interleukin-12, interleukin-6, tumor necrosis factor, and chemokines; natural killer cells destroy damaged host cells (e.g., tumor cells and virus-infected cells); and macrophages consume substantial numbers of bacteria or other cells or microorganisms.
[0055] In some embodiments, the NSG TM Flt3 null Tg(Hu-FLT3L) mice were TMIncreased percentage of human CD123 versus control mice + In some embodiments, the NSGs include plasmacytoid dendritic cells. TM Flt3 null Human CD123 in Tg(Hu-FLT3L) mice + The percentage of plasmacytoid dendritic cells in NSG TM Increase by at least 25% compared to control mice. For example, TM Flt3 null Human CD123 in Tg(Hu-FLT3L) mice + The percentage of plasmacytoid dendritic cells in NSG TM In some embodiments, the NSG expression level may be increased by at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 100% relative to control mice. TM Flt3 null Human CD123 in Tg(Hu-FLT3L) mice + The percentage of plasmacytoid dendritic cells in NSG TM In some embodiments, the NSG TM Flt3 null Human CD123 in Tg(Hu-FLT3L) mice + The percentage of plasmacytoid dendritic cells in NSG TM In some embodiments, the NSG TM Flt3 null Human CD123 in Tg(Hu-FLT3L) mice + The percentage of plasmacytoid dendritic cells in NSG TM Increase by 25%-100%, 25%-75%, 25%-50%, 50%-100%, 50%-75%, or 75%-100% relative to control mice.
[0056] In some embodiments, the NSG TM Flt3 null Tg(Hu-FLT3L) mice were TM Increased percentage of human CD56 vs. control mice + In some embodiments, the NSGs include natural killer cells. TM Flt3 null Human CD56 in Tg(Hu-FLT3L) mice + The percentage of natural killer cells is NSG TM Increase by at least 25% compared to control mice. For example, TM Flt3 null Human CD56 in Tg(Hu-FLT3L) mice + The percentage of natural killer cells is NSG TM In some embodiments, the NSG expression level may be increased by at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 100% relative to control mice. TM Flt3 null Human CD56 in Tg(Hu-FLT3L) mice + The percentage of natural killer cells is NSG TM In some embodiments, the NSG TM Flt3 null Human CD56 in Tg(Hu-FLT3L) mice + The percentage of natural killer cells is NSG TM In some embodiments, the NSG TM Flt3 null Human CD56 in Tg(Hu-FLT3L) mice +The percentage of natural killer cells is NSG TM Increase by 25%-100%, 25%-75%, 25%-50%, 50%-100%, 50%-75%, or 75%-100% relative to control mice.
[0057] In some embodiments, the NSG TM Flt3 null Tg(Hu-FLT3L) mice were TM Increased percentage of human CD14 vs. control mice + In some embodiments, the NSGs include monocytes and macrophages. TM Flt3 null Human CD14 in Tg(Hu-FLT3L) mice + Monocyte-macrophage percentages in NSG TM Increase by at least 25% compared to control mice. For example, TM Flt3 null Human CD14 in Tg(Hu-FLT3L) mice + Monocyte-macrophage percentages in NSG TM In some embodiments, the NSG expression level may be increased by at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 100% relative to control mice. TM Flt3 null Human CD14 in Tg(Hu-FLT3L) mice + Monocyte-macrophage percentages in NSG TM In some embodiments, the NSG TM Flt3 null Human CD14 in Tg(Hu-FLT3L) mice + Monocyte-macrophage percentages in NSG TMIn some embodiments, the NSG TM Flt3 null Human CD14 in Tg(Hu-FLT3L) mice + Monocyte-macrophage percentages in NSG TM Increase by 25%-100%, 25%-75%, 25%-50%, 50%-100%, 50%-75%, or 75%-100% relative to control mice.
[0058] In some embodiments, the NSG TM Flt3 null Tg(Hu-FLT3L) mice were TM Increased percentage of human CD11C vs. control mice + HLA-DR + In some embodiments, the NSGs include myeloid dendritic cells. TM Flt3 null Human CD11C in Tg(Hu-FLT3L) mice + HLA-DR + The percentage of myeloid dendritic cells in NSG TM Increase by at least 25% compared to control mice. For example, TM Flt3 null Human CD11C in Tg(Hu-FLT3L) mice + HLA-DR + The percentage of myeloid dendritic cells in NSG TM In some embodiments, the NSG expression level may be increased by at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 100% relative to control mice. TM Flt3 null Human CD11C in Tg(Hu-FLT3L) mice + HLA-DR + The percentage of myeloid dendritic cells in NSGTM In some embodiments, the NSG TM Flt3 null Human CD11C in Tg(Hu-FLT3L) mice + HLA-DR + The percentage of myeloid dendritic cells in NSG TM In some embodiments, the NSG TM Flt3 null Human CD11C in Tg(Hu-FLT3L) mice + HLA-DR + The percentage of myeloid dendritic cells in NSG TM Increase by 25%-100%, 25%-75%, 25%-50%, 50%-100%, 50%-75%, or 75%-100% relative to control mice.
[0059] Methods for generating transgenic animals In some aspects, the present specification provides a method for generating a transgenic animal that expresses human FLT3L.Transgenic animal, as used herein, refers to an animal that has a foreign (exogenous) nucleic acid (e.g., transgene) inserted (integrated) into its genome.In some embodiments, the transgenic animal is a transgenic rodent (e.g., mouse or rat).In some embodiments, the transgenic animal is a mouse.For example, the method for generating a transgenic mouse is well known. Three traditional methods used to generate transgenic animals include DNA microinjection (Gordon and Ruddle, Science 1981: 214: 1244-124, incorporated herein by reference), embryonic stem cell-mediated gene transfer (Gossler et al., Proc. Natl. Acad. Sci. 1986; 83: 9065-9069, incorporated herein by reference), and retrovirus-mediated gene transfer (Jaenisch, Proc. Natl. Acad. Sci. 1976; 73: 1260-1264, incorporated herein by reference), any of which may be used as provided herein.
[0060] The nucleic acid encoding human FLT3L, in some embodiments, comprises a human FLT3L transgene comprising a promoter (e.g., a constitutively active promoter) operably linked to a nucleotide sequence encoding human FLT3L. In some embodiments, the nucleic acid encoding human FLT3L used to generate a transgenic animal (e.g., a mouse) is present on a vector (e.g., a plasmid, a bacterial artificial chromosome (BAC), or a yeast artificial chromosome (YAC)) that is delivered, for example, to the pronucleus / nucleus of a fertilized embryo where the nucleic acid is randomly integrated into the animal genome. In some embodiments, the nucleic acid (e.g., carried on a BAC) is a NSG TM To generate Tg(Hu-FLT3L) mice, NSG TMThe nucleic acid encoding human FLTL3 is delivered to the fertilized embryo of mouse.After the fertilized embryo is injected, the fertilized embryo is transferred to a pseudopregnant female mouse, and then the offspring is born that comprises the nucleic acid encoding human FLTL3.The presence or absence of the nucleic acid encoding human FLTL3 can be confirmed, for example, by using any number of genotyping methods (for example, sequencing and / or genomic PCR).
[0061] Also provided herein is a method for inactivating an endogenous Flt3 allele. In some embodiments, an endogenous Flt3 allele is inactivated in a transgenic animal. In some embodiments, the transgenic animal is an NSG TM Tg(Hu-FLT3L) mice. Thus, in some embodiments, the method comprises: TM Inactivation of the mouse Flt3 allele in Tg(Hu-FLT3L) mice results in the expression of NSG TM Flt3 null The method includes generating Tg(Hu-FLT3L) mice. Methods of gene (allele) inactivation are known, and any of them can be used as provided herein. In some embodiments, gene / genome editing methods are used. The engineered nuclease-based gene editing system that can be used as provided herein includes, for example, clustered regularly interspaced short palindromic repeat (CRISPR) system, zinc finger nuclease (ZFN), and transcription activator-like effector nuclease (TALEN). See, e.g., Carroll D Genetics. 2011; 188(4): 773-782; Joung JK et al. Nat Rev Mol Cell Biol. 2013; 14(1): 49-55; and Gaj T et al. Trends Biotechnol. 2013 Jul; 31(7): 397-405, each of which is incorporated herein by reference.
[0062] In some embodiments, the CRISPR system can be used to inactivate, for example, an endogenous Flt3 allele to generate an NSG TM Flt3 null Tg(Hu-FLT3L) mice are used to generate. See, for example, Harms DW et al., Curr Protoc Hum Genet. 2014; 83: 15.7.1-15.7.27; and Inui M et al., Sci Rep. 2014; 4: 5396, each of which is incorporated herein by reference. For example, Cas9 mRNA or protein and one or more guide RNAs (gRNAs) can be directly injected into mouse embryos to generate precise genome editing in the Flt3 gene. Mice that develop from these embryos are genotyped or sequenced to determine whether they have the desired mutation(s), and embryos carrying the mutations are bred to confirm germline transmission.
[0063] The CRISPR / Cas system is a naturally occurring defense mechanism in prokaryotes that has been repurposed as an RNA-guided-DNA-targeting platform for gene editing. The engineered CRISPR system contains two major components: a guide RNA (gRNA) and a CRISPR-associated endonuclease (e.g., a Cas protein). The gRNA is a short synthetic RNA that is composed of a scaffold sequence for nuclease binding and a user-defined nucleotide spacer (e.g., about 15-25 nucleotides, or about 20 nucleotides) that defines the genomic target to be modified. Thus, the genomic target of the Cas protein can be altered by simply changing the target sequence present in the gRNA. In some embodiments, the CRISPR-associated endonuclease is selected from Cas9, Cpf1, C2c1, and C2c3. In some embodiments, the Cas nuclease is Cas9.
[0064] A guide RNA comprises at least a spacer sequence that hybridizes (or binds) to a target nucleic acid sequence (e.g., a region of an Flt3 allele, e.g., a promoter sequence, a coding sequence, or a non-coding sequence), and a CRISPR repeat sequence that binds the endonuclease and guides the endonuclease to the target nucleic acid sequence. As will be understood by those skilled in the art, each gRNA is designed to include a spacer sequence that is complementary to its genomic target sequence (e.g., a region of the Flt3 allele). See, for example, Jinek et al., Science, 2012; 337: 816-821 and Deltcheva et al. See Nature, 2100; 471: 602-607, each of which is incorporated herein by reference. In some embodiments, the gRNA used in the methods provided herein binds to exon 6 of a mouse Flt3 allele. In some embodiments, the gRNA used in the methods provided herein binds to exon 7 of a mouse Flt3 allele. In some embodiments, the gRNA used in the methods provided herein binds to exon 8 of a mouse Flt3 allele. In some embodiments, multiple gRNAs are used to target multiple regions of the Flt3 allele. In some embodiments, two gRNAs are used, one that binds to the Flt3 allele exon 6 and one that binds to exon 8. In some embodiments, the gRNA of the present disclosure comprises the nucleotide sequence of SEQ ID NO:1. In some embodiments, the gRNA of the present disclosure comprises the nucleotide sequence of SEQ ID NO:2.
[0065] How to use The mouse models provided herein can be used for any number of applications. For example, TM Flt3 null --Tg(Hu-FLT3L) mice can be used to test how a particular drug (e.g., a therapeutic agent) or medical procedure (e.g., a tissue transplant) affects the human innate immune system (e.g., human innate immune cell responses).
[0066] In some embodiments, the NSG TM Flt3 null The NSG-Tg(Hu-FLT3L) mice are used to evaluate the effects of drugs on the development of the human innate immune system. TM Flt3 null Provided herein is a method that includes administering a drug to a Hu-FLT3L-Tg(Hu-FLT3L) mouse and evaluating the effect of the drug on human innate immune system development in the mouse. The effect of the drug can be evaluated, for example, by measuring human innate immune cell (e.g., T cell and / or dendritic cell) response (e.g., cell death, cell signaling, cell proliferation, etc.). Non-limiting examples of drugs include therapeutic agents (e.g., anti-cancer agents and anti-inflammatory agents), prophylactic agents (e.g., immunogenic compositions (e.g., vaccines)).
[0067] In another embodiment, the NSG TM Flt3 null NSG-Tg(Hu-FLT3L) mice are used to evaluate immunotherapeutic responses to human tumors. TM Flt3 null Provided herein is a method comprising administering a drug to a Hu-FLT3L-Tg(Hu-FLT3L) mouse and evaluating the effect of the drug on the human innate immune system and / or tumor in the mouse. The effect of the drug can be evaluated by measuring human innate immune cell (e.g., T cell and / or dendritic cell) response and / or tumor cell response (e.g., cell death, cell signaling, cell proliferation, etc.). In some embodiments, the drug is an anti-cancer drug.
[0068] In yet another embodiment, the NSG TM Flt3 null NSG-Tg(Hu-FLT3L) mice are used to evaluate human innate immune responses to infectious microorganisms. TM Flt3 nullProvided herein are methods that include exposing a Hu-Tg(Hu-FLT3L) mouse to an infectious microorganism (e.g., bacteria and / or virus) and evaluating the effect of the infectious microorganism on the human innate immune response. The effect of the infectious microorganism can be evaluated by measuring human innate immune cell (e.g., T cell and / or dendritic cell) responses (e.g., cell death, cell signaling, cell proliferation, etc.). These methods can further include administering a drug or antimicrobial agent (e.g., an antibacterial or antiviral agent) to the mouse and evaluating the effect of the drug or antimicrobial agent on the infectious microorganism.
[0069] In yet a further embodiment, the NSG TM Flt3 null NSG-Tg(Hu-FLT3L) mice are used to evaluate human immune responses to tissue transplantation. TM Flt3 null Provided herein is a method that includes transplanting the human innate immune response into a human innate immune response. The effect of transplanted tissue can be evaluated by measuring the human innate immune cell (e.g., T cell and / or dendritic cell) response (e.g., cell death, cell signaling, cell proliferation, etc.) to the transplanted tissue. EXAMPLES
[0070] Example 1: NSG TM Generation of -Tg(Hu-FLT3L) mice Transgenic NSG expressing human FLT3 ligand (FLT3L) to support human DC development and innate immune function TM To generate these transgenic mouse lines, a 13.8 kilobase (kb) clone derived from bacterial artificial chromosome (BAC) clone RP11-360G9 from CHORI BACPAK was used. The BamHI restriction fragment was subcloned into pBluescript to eliminate other genes in the BAC. The purified and linearized DNA was then transformed into NOD.Cg-Prkdc scid Il2rg tm1Wjl / SzJ(NSG TM ) injected into the pronuclei of fertilized eggs.
[0071] Eleven founders were identified by PCR. Of these founder lines, four (lines 3, 7, 8, and 10) had detectable levels of circulating human FLT3L when tested by enzyme-linked immunosorbent assay (ELISA). These founders were mated with NSG non-transgenic mice. The transgenic offspring of this mating were tested by ELISA for circulating human FLT3L levels. Levels of FLT3L in transgenic NSG mice (lines 7 and 8) that were hemizygous or homozygous for the human FLT3L transgene ranged from 400 to 600 pg / mL (Figure 1).
[0072] Example 2: NSG TM -Tg(Hu-FLT3L) mice exhibit impaired human HSC development Then, transgenic NSG expressing human FLT3L TM Mouse (NSG TM -Tg(Hu-FLT3L)) and human umbilical cord blood CD34 + HSCs were engrafted. NSG TM -Tg(Hu-FLT3L) mice and NSG TM A cohort of non-transgenic control mice was sublethally irradiated (200 cGy) and injected intravenously with 100,000 human cord blood HSCs. Flow cytometry of peripheral blood from engrafted mice was performed at 6, 9, 12, and 15 weeks post-engraftment. Unexpectedly, human CD45 + The percentage of cells that were NSG at all time points tested TM Compared to the control, the above NSG TM-Tg(Hu-FLT3L) mice showed significantly lower levels of IFN-γ-γ and IFN-γ-γ in the control mice (Figure 2).
[0073] Example 3: NSG TM Flt3 null Generation of Tg(Hu-FLT3L) mice NSG TM To test whether the reduced human HSC engraftment in -Tg(Hu-FLT3L) mice is the result of human FLT3L activating host mouse DCs and possibly other innate immune mouse components, the gene encoding the mouse FLT3 receptor (Flt3) was knocked out (to prevent human FLT3L from binding to the mouse FLT3 receptor and activating mouse innate immunity). Without being bound by theory, in the absence of the mouse FLT3 receptor, both human FLT3L and mouse FLT3L would be available to bind to the human FLT3 receptor.
[0074] The mouse Flt3 gene encoding the FLT3 receptor was transfected into the NSG TM The mouse Flt3L transgene was directly knocked out in the -Tg(Hu-FLT3L) homozygous line. To knock out the mouse Flt3 gene, two single guide RNAs (sgRNAs, see Table 1 below) were designed to target exons 6 and 8, which should eliminate the immunoglobulin-like domain even if the transcript is retained and hypomorphic. The sgRNAs were designed using breaking Cas (6) and Zifit (7) software to minimize the possibility of off-target cleavage, and were also checked against human sequences to ensure that the human FLT3L transgene was not targeted. Both sgRNAs were designed as Tru-Guides ("truncated"), each with only a 19-nt recognition site, to further reduce the possibility of off-target cleavage (8). The sgRNAs were prepared as previously described (9).
[0075] Screening for mouse Flt3 knockouts was performed using PCR primers (see Table 1 below) flanking the region of interest (e.g., exons 6-8). The PCR primers above yield a 1942 base pair (bp) wild-type amplicon with an expected size of 670 bp for the mutant dropout ("DO") allele. After PCR, samples were screened by Sanger sequencing using the same primers. Three founders carrying the knockout allele were identified by PCR and subsequently sequenced. Three knockout lines were established by crossing N2 mice derived from the founder with the largest deletion (lines 1, 2, and 4). Knockouts were typed by PCR and finally, a single knockout line was expanded, validated, and characterized (NPD.Cg-Flt3 em1Mvw Prkdc scid Il2rg tm1Wjl Tg(Hu-FLT3L)7Sz), NSG TM Flt3 null Abbreviated as Tg(Hu-FLT3L) mice.
[0076] Modified Flt3 null The allele lost 1500 bp beginning before exon 6 and ending just before the end of exon 8. The sequence of the deleted gene is shown as SEQ ID NO:5 (the 1500 base pairs are in the NSG TM Flt3 null The mouse Flt3 receptor gene was deleted in the mouse Flt3-Tg(Hu-FLT3L) mouse. null The PCR product obtained for the allele is 442 bp. The sequence of this PCR product is shown as SEQ ID NO:6 (PCR product resulting from targeted mouse Flt3 gene deletion). The mouse FLT3 receptor is referred to as cluster of differentiation CD135. TM Flt3 null Tg(Hu-FLT3L) mice were cultured using CD135 + The absence of murine FLT3 was verified by flow cytometry of bone marrow dendritic cells by the absence of multipotent progenitor (MPP3) cells (Figure 3).
[0077] [Table 1]
[0078] Example 4: NSG TM Flt3 null Tg(Hu-FLT3L) mice support dendritic cell development The above NSG expresses the human FLT3L transgene and lacks the mouse FLT3 receptor. TM Flt3 null ELISA assays of serum from Tg(Hu-FLT3L) mice showed levels of human FLT3L ranging from 15,175±1,137pg / mL to 17,120±92.7pg / mL. TM Serum from non-transgenic control mice did not show detectable FLT3L levels (Figures 4A-4B). TM Flt3 null In Tg(Hu-FLT3L), the range was 6,000-8,000 pg / mL, whereas in NSG TM Mouse FLT3L levels in controls were approximately 1,000 pg / mL.
[0079] The above NSG TM Flt3 null Tg(Hu-FLT3L) mice express human CD34 + To determine their ability to support engraftment by HSCs and the development of a human immune system, 8- to 12-week-old NSGs were cultured in vitro. TM Flt3 null Groups of Tg(Hu-FLT3L) mice (n = 8) and NSG TM A group of control mice (n=10) was sublethally irradiated (200cGy) and injected with 100,000 human umbilical cord blood CD34 + HSCs were injected intravenously (IV). Flow cytometry analysis of peripheral blood from engrafted mice at 6, 9, 12, 15, and 18 weeks post-engraftment was performed using the NSG TM Flt3 null Tg(Hu-FLT3L) and NSGTM Control mice were transfected with human CD45 + showed similar percentages of white blood cells, but + In the cell population, the above NSG TM Flt3 null Tg(Hu-FLT3L) mice express human CD3 + T cells and human CD33 + Both had significantly increased percentages of myeloid cells (Figures 5A-5D and Figures 8A-8C).
[0080] NSG TM Flt3 null Tg(Hu-FLT3L) mice also express human CD123 + Plasmacytoid dendritic cells, CD56 + Human natural killer (NK) cells, CD14 + Human monocytes / macrophages, and CD11C + HLA-DR + We showed an increased percentage of human myeloid dendritic cells (Figs. 6A-6D and 8D-8F). Furthermore, histochemical analysis of tissues from engrafted mice unexpectedly demonstrated that NSG TM Flt3 null Human CD45 expression in the small intestine of Tg(Hu-FLT3L) mice + Mucosal engraftment of the cells was demonstrated (Figure 7).
[0081] array CCAACCTGAACTGTATGGAGATAGCTTGTCTATGGGGAAAAAAAATCACCAAATAAAATAAAATCTAAATATTAAATAATAAAGTAATACTGTAACATATTACATTACAGAGTAGCTAGCTGGTCCCTGCAGATTCCAGGCTGGATACAGTTGAGTTAATTTTTCATCTGCTCTTTTTCCATCCCTAAAAATATACTTTGTAACTTCATCCCCTAAACATACTGGGTCCCCCACCCATCCTAGGTAACGGCTCACGAAATTTGGGTTGGTTGTTTGTTTTTTAATGCTGTCCTGGAACTCGCTGTGTAGATTGGTTGGCCTTGAACTCACAGAAATCTACCAGCATCTGCCTCCCAGTGCTGGGATTAAAGGCCACAGGCCACCAAGCTTGACTCTGCTTGTGTGTCTTAGTGGGCTTTCCCTGTGG (sequence number 6)
[0082] References 1. P. Tsapogas, C. J. Mooney, G. Brown, A. Rolink, The Cytokine Flt3-Ligand in Normal and Malignant Hematopoiesis. International journal of molecular sciences 18, (2017). 2. C. J. Mooney, A. Cunningham, P. Tsapogas, K. M. Toellner, G. Brown, Selective Expression of Flt3 within the Mouse Hematopoietic Stem Cell Compartment. International journal of molecular sciences 18, (2017). 3. L. D. Shultz, M. A. Brehm, J. V. Garcia-Martinez, D. L. Greiner, Humanized mice for immune system investigation: progress, promise and challenges. Nat Rev Immunol 12, 786-798 (2012). 4. K. Palucka, J. Banchereau, Cancer immunotherapy via dendritic cells. Nature reviews. Cancer 12, 265-277 (2012). 5. J. S. Do, B. Min, IL-15 produced and trans-presented by DCs underlies homeostatic competition between CD8 and {gamma}{delta} T cells in vivo. Blood 113, 6361-6371 (2009). 6. JC Oliveros et al., Breaking-Cas-interactive design of guide RNAs for CRISPR-Cas experiments for ENSEMBL genomes. Nucleic acids research 44, W267-271 (2016). 7. PD Hsu et al., DNA targeting specificity of RNA-guided Cas9 nucleases. Nature biotechnology 31, 827--832 (2013). 8. Y. Fu, JD Sander, D. Reyon, VM Cascio, JK Joung, Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Nature biotechnology 32, 279-284 (2014). 9. BE Low, PM Kutny, MV Wiles, Simple, Efficient CRISPR-Cas9-Mediated Gene Editing in Mice: Strategies and Methods. Methods Mol Biol 1438, 19-53 (2016).
[0083] All references, patents, and patent applications disclosed herein are incorporated by reference with respect to the subject matter, and each is cited with respect to said subject matter, which may in some cases include the entirety of the document.
[0084] The indefinite articles "a" and "an," as used in the specification and claims, unless clearly indicated otherwise, should be understood to mean "at least one."
[0085] It should also be understood that, unless expressly indicated otherwise, in any method that includes more than one step or act claimed herein, the order of the steps or acts of the method is not necessarily limited to the order in which the steps or acts of the method are described.
[0086] In the claims and in the above specification, all transitional phrases (e.g., "comprising," "including," "carrying," "having," "containing," "involving," "holding," "composed of," etc.) are to be understood to mean without open-ended limitations, i.e., including, but not limited to. Only the transitional phrases "consisting of" and "consisting essentially of" are intended to be closed or semi-closed transitional phrases, respectively, as set forth in the U.S. Patent and Trademark Office Guidelines for Patent Examining Procedures, Section 2111.03.
[0087] The terms "about" and "substantially" preceding a numerical value mean ±10% of the stated numerical value.
[0088] When a range of values is provided, each value between the upper and lower limits of the range is specifically contemplated and described herein. In certain embodiments, for example, the following are provided: (Item 1) NOD.Cg-Prkdc scid Il2rg tm1Wjl / SzJ (NOD scid gamma) mice, said mice comprising: A nucleic acid encoding human FLT3L, and Inactivated mouse Flt3 allele, Including a mouse. (Item 2) 2. The mouse of item 1, wherein the mouse comprises a genomic modification that inactivates the mouse Flt3 allele. (Item 3) 3. The mouse of item 2, wherein the genomic modification is in at least one region of the mouse Flt3 allele selected from a coding region, a non-coding region, and a regulatory region. (Item 4) 4. The mouse of item 3, wherein the genomic modification is in a coding region of at least one of the mouse Flt3 alleles. (Item 5) 5. The mouse of item 4, wherein the genomic modification is in exon 6, exon 7, and / or exon 8. (Item 6) 6. The mouse according to any one of items 2 to 5, wherein the genome modification is selected from genome deletion, genome insertion, genome replacement, and a combination thereof. (Item 7) 7. The mouse of item 6, wherein the genomic modification is a genomic deletion. (Item 8) 8. The mouse of item 7, wherein the mouse Flt3 allele comprises a genomic deletion of nucleotide sequences in exon 6, exon 7, and exon 8. (Item 9) 9. The mouse of item 8, wherein the nucleic acid sequence of SEQ ID NO:5 is deleted from the mouse Flt3 allele. (Item 10) 10. The mouse of item 9, wherein the modified mouse Flt3 allele comprises the nucleic acid sequence of SEQ ID NO:6. (Item 11) 11. The mouse according to any one of items 1 to 10, wherein the nucleic acid encoding human FLT3L comprises a human FLT3L transgene. (Item 12) 12. The mouse of item 11, wherein the human FLT3L transgene comprises the nucleic acid sequence of SEQ ID NO:7. (Item 13) 13. The mouse according to any one of items 1 to 12, wherein the mouse expresses human FLT3L. (Item 14) 14. The mouse of item 13, wherein the human FLT3L is expressed at a level of at least 10,000 pg / ml. (Item 15) 15. The mouse according to item 14, wherein the human FLT3L is expressed at a level of 10,000 pg / ml to 30,000 pg / ml. (Item 16) 16. The mouse according to item 14 or 15, wherein the human FLT3L is expressed at a level of 15,000±1000 pg / mL to 17,000±100 pg / ml. (Item 17) 17. The mouse according to any one of items 1 to 16, wherein the mouse expresses mouse FLT3L. (Item 18) 18. The mouse of item 17, wherein the mouse FLT3L is expressed at a level of at least 2,000 pg / ml. (Item 19) 19. The mouse according to item 18, wherein the mouse FLT3L is expressed at a level of 5,000 pg / ml to 10,000 pg / ml. (Item 20) 19. The mouse according to item 18, wherein the mouse FLT3L is expressed at a level of 6,000 pg / ml to 8,000 pg / ml. (Item 21) 21. The mouse according to any one of items 1 to 20, wherein the mouse does not express a detectable level of mouse FLT3. (Item 22) 22. The mouse of any one of items 1 to 21, wherein the detectable level of mouse FLT3 expressed by the mouse is less than 1,000 pg / ml. (Item 23) The mice express detectable amounts of CD135 + 23. The mouse of any one of items 1 to 22, which lacks multipotent progenitor cells. (Item 24) Human CD34 + 24. The mouse of any one of items 1 to 23, further comprising hematopoietic stem cells. (Item 25) The human CD34 +25. The mouse of item 24, wherein the hematopoietic stem cells are derived from human umbilical cord blood, bone marrow, or mobilized peripheral blood. (Item 26) The mouse expresses human CD45 + 26. The mouse of any one of items 1 to 25, comprising a population of cells. (Item 27) Human CD45 + The population of cells comprises human CD45 + / CD3 + T cells and / or human CD45 + / CD33 + 27. The mouse of item 26, comprising myeloid cells. (Item 28) Human CD45 + The population of cells contained an increased percentage of human CD45 + / CD3 + 28. The mouse of item 27, comprising T cells. (Item 29) Human CD45 in the mice + / CD3 + 29. The mouse of item 28, wherein the percentage of T cells is increased by at least 25%, at least 50%, or at least 100%. (Item 30) Human CD45 + The population of cells contained an increased percentage of human CD45 + / CD33 + 30. The mouse of any one of items 27 to 29, comprising myeloid cells. (Item 31) Human CD45 in the mouse + / CD33 + 31. The mouse of paragraph 30, wherein said percentage of myeloid cells is increased by at least 25%, at least 50%, or at least 100%. (Item 32) The mice were either NOD scid gamma control mice or NOD scid Increased percentage of human CD123 versus gamma-Hu-FLT3L control mice + 32. The mouse according to any one of items 1 to 31, comprising plasmacytoid dendritic cells. (Item 33) Human CD123 in the mouse + 33. The mouse of item 32, wherein the percentage of plasmacytoid dendritic cells is increased by at least 25%, at least 50%, or at least 100%. (Item 34) The mice were either NOD scid gamma control mice or NOD scid Increased percentage of human CD56 versus gamma-Hu-FLT3L control mice + 34. The mouse of any one of items 1 to 33, comprising natural killer cells. (Item 35) Human CD56 in the mouse + 35. The mouse of item 34, wherein the percentage of natural killer cells is increased by at least 25%, at least 50%, or at least 100%. (Item 36) The mice were either NOD scid gamma control mice or NOD scid Increased percentage of human CD14 relative to gamma-Hu-FLT3L control mice + 36. The mouse according to any one of items 1 to 35, comprising monocytes / macrophages. (Item 37) Human CD14 in the mice + 37. The mouse of item 36, wherein the percentage of monocytes-macrophages is increased by at least 25%, at least 50%, or at least 100%. (Item 38) The mice were either NOD scid gamma control mice or NOD scid Increased percentage of human CD11C versus gamma-Hu-FLT3L control mice + HLA-DR + 38. The mouse according to any one of items 1 to 37, comprising myeloid dendritic cells. (Item 39) Human CD11C in the mouse + HLA-DR + 39. The mouse of paragraph 38, wherein the percentage of myeloid dendritic cells is increased by at least 25%, at least 50%, or at least 100%. (Item 40) The mice express human CD45 in the small intestine of the mice. + 40. The mouse according to any one of items 1 to 39, which exhibits mucosal engraftment of the cells. (Item 41) A method for treating a mouse according to any one of items 1 to 23, comprising the steps of: sublethally irradiating the mouse with human CD34; + The method comprises the step of injecting hematopoietic stem cells. (Item 42) Item 43. The method according to item 41, further comprising administering a drug of interest to the mouse. 43. The method of claim 42, further comprising evaluating the effect of the agent on human immune cells in the mouse. (Item 44) 44. The method of claim 43, wherein the human immune cells are selected from T cells, dendritic cells, natural killer cells, and macrophages. (Item 45) NOD.Cg-Prkdc scid Il2rg tm1Wjl Injecting a nucleic acid encoding human FLT3L into the pronuclei of NSG / SzJ (NOD scid gamma) mice; 46. A method for producing a Tg(Hu-FLT3L) mouse, and inactivating a mouse Flt3 allele in the NSG Tg(Hu-FLT3L) mouse. NOD.Cg-Prkdc scid Il2rg tm1WjlInactivation of the mouse Flt3 allele in / SzJ (NOD scid gamma) mice results in the expression of NSG Flt3 null generating a mouse, and null A method comprising the step of injecting a nucleic acid encoding human FLT3L into the pronucleus of a mouse. (Item 47) NOD.Cg-Prkdc, which contains a nucleic acid encoding human FLT3L and an inactivated endogenous Flt3 allele scid Il2rg tm1Wjl / SzJ cells. (Item 48) A transgenic rodent comprising the cell of item 47, optionally wherein the transgenic rodent is a transgenic mouse. (Item 49) Prkdc scid Homozygous for Il2rg tm1Wjl Homozygous for Flt3 null Female mice homozygous for the Prkdc transgene and homozygous for the human FLT3L transgene were scid Homozygous for X-linked Il2rg tm1Wjl Hemizygous for Flt3 null and a male mouse homozygous for the human FLT3L transgene to generate offspring mice. (Item 50) A gRNA targeting mouse Flt3, optionally wherein the gRNA targets exon 6 or exon 8 or mouse Flt3. (Item 51) 51. The gRNA of item 50, wherein the gRNA comprises the sequence of SEQ ID NO: 1 or SEQ ID NO: 2. (Item 52) 52. A mouse oocyte comprising the gRNA of item 50 or 51, optionally wherein the mouse oocyte is fertilized. (Item 53) A mouse oocyte comprising a first gRNA targeting exon 6 of mouse Flt3 and a second gRNA targeting exon 8 of mouse Flt3, optionally wherein the mouse oocyte is fertilized. (Item 54) 54. The mouse oocyte of item 52 or 53, further comprising Cas9 mRNA and / or Cas9 protein. (Item 55) 55. The mouse oocyte according to any one of items 52 to 54, further comprising a human FLT3L transgene.
Claims
[Claim 1] The invention described in the specification.
Citation Information
Patent Citations
Method for producing humanized non-human mammals
JP2012531896A
Boosting human dendritic cell development, homeostasis and function in xenografted immunodeficient mice
US20120094312A1
